Contact Information: Contact Information: Stephen Feldschuh 212-330-8515 Chief Operating Officer Email Contact Diane Meegan 212-330-8512 Investor Relations Email Contact
Daxor Announces Florida Cardiovascular Institute of Tampa, FL Acquires BVA-100 Blood Volume Analyzer
| Source: Daxor Corp.
NEW YORK, NY -- (MARKET WIRE) -- January 25, 2007 -- Daxor Corporation (AMEX : DXR ), a medical
instrumentation and biotechnology company, today announced the receipt of a
signed trial agreement from the Florida Cardiovascular Institute of Tampa,
Florida.
The Florida Cardiovascular Institute (FCI) provides state-of-the-art,
compassionate health care ranging from preventative medicine to the
treatment of the most complex heart and vascular diseases. As the region's
only private cardiology practice offering a blood volume analysis (BVA),
FCI reaffirms its commitment to providing the highest quality health
services available. Through the years, FCI Heart Center has earned its
highly regarded reputation in the community by integrating the latest
technology and most effective techniques into treatment so their patients
can lead healthier and more active lives.
"We are extremely excited to begin working with FCI, especially as this
will be Daxor's first BVA-100 within a private practice setting in
Florida," noted John Reyes-Guerra, Daxor's Vice President of Sales and
Marketing. Mr. Reyes-Guerra also noted that, "FCI has been an innovator in
cardiovascular disease management and treatment through their dedication to
patient-oriented research through the Florida Cardiovascular Institute and
Research Foundation and their relationships with leading academic and
community institutions committed to improving patient care."
The Daxor Blood Volume Analyzer BVA-100 permits FCI to offer its patients
along with area physicians treating various heart and vascular diseases to
accurately measure and then treat a patient's volume derangement. Previous
published studies in heart failure have demonstrated that patients who have
had their blood volume diagnosed and treated to a normal blood volume by a
BVA have significant improved outcomes than patients who remain "volume
overloaded."
Daxor Corporation manufactures and markets the BVA-100, a semi-automated
Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex,
Daxor's single use diagnostic kit. For more information regarding Daxor
Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website
www.Daxor.com.